よむ、つかう、まなぶ。
【参考資料4】抗微生物薬適正使用の手引き 第三版 本編 (129 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of
America/American Thoracic Society consensus guidelines on the management of
community-acquired pneumonia in adults. Clin Infect Dis. Mar 1 2007;44 Suppl 2(Suppl
2):S27-72.
33. Thom KA, et al. Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in
Hospitalized Patients. Clin Infect Dis. 2019;68(9):1581–1584.
34. Yoshida H, Motohashi T, De Bus L, et al. Use of broad-spectrum antimicrobials for more than
72 h and the detection of multidrug-resistant bacteria in Japanese intensive care units: a
multicenter retrospective cohort study. Antimicrob Resist Infect Control. Sep 29
2022;11(1):119.
35. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With
Antibiotic Use in Hospitalized Patients. JAMA Intern Med. Sep 1 2017;177(9):1308-1315.
36. Dantes R, et al. Association Between Outpatient Antibiotic Prescribing Practices and
Community-Associated Clostridium difficile Infection. Open Forum Infect Dis. 2015 Aug
11;2(3):ofv113.
37. Ho C-Y, Lee C-H, Yang C-Y, Hsieh C-C, Ko W-C, Lee C-C. Antimicrobial escalation is not
beneficial for Gram-negative bacteremia in adults who remained critically ill after appropriate
empirical therapy. Journal of infection and chemotherapy: official journal of the Japan Society
of Chemotherapy. 2020 Sep;26(9):933-940.
38. Roger P-M, et al. Risk Factors for Unnecessary Antibiotic Therapy: A Major Role for Clinical
Management. Clin Infect Dis. 2019 Jul;69(3):466-472.
39. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr.
2021 Oct;44(5):161-164.
40. Bassetti M, Vena A, Giacobbe DR, et al. Risk Factors for Intra-Abdominal Candidiasis in
Intensive Care Units: Results from EUCANDICU Study. Infect Dis Ther. 2022 Apr;11(2):827840.
41. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia
due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011
Aug;39(4):319-325.
42. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial
therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011
4th European Conference on Infections in Leukemia. Haematologica. 2013 Dec;98(12):18261835.
43. Ly WJ, Brown EE, Pedretti Z, Auten J, Wilson WS. Evaluation of early de-escalation of
empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large
academic medical center.J Oncol Pharm Pract. 2023 Mar;29(2):305-310.
44. Petteys MM, Kachur E, Pillinger KE, He J, Copelan EA, Shahid Z. Antimicrobial deescalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of
unknown origin. J Oncol Pharm Pract. Apr 2020;26(3):632-640.
45. Ohji G, Doi A, Yamamoto S, Iwata K. Is de-escalation of antimicrobials effective? A
systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:71-79.
129
第三版
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of
America/American Thoracic Society consensus guidelines on the management of
community-acquired pneumonia in adults. Clin Infect Dis. Mar 1 2007;44 Suppl 2(Suppl
2):S27-72.
33. Thom KA, et al. Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in
Hospitalized Patients. Clin Infect Dis. 2019;68(9):1581–1584.
34. Yoshida H, Motohashi T, De Bus L, et al. Use of broad-spectrum antimicrobials for more than
72 h and the detection of multidrug-resistant bacteria in Japanese intensive care units: a
multicenter retrospective cohort study. Antimicrob Resist Infect Control. Sep 29
2022;11(1):119.
35. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With
Antibiotic Use in Hospitalized Patients. JAMA Intern Med. Sep 1 2017;177(9):1308-1315.
36. Dantes R, et al. Association Between Outpatient Antibiotic Prescribing Practices and
Community-Associated Clostridium difficile Infection. Open Forum Infect Dis. 2015 Aug
11;2(3):ofv113.
37. Ho C-Y, Lee C-H, Yang C-Y, Hsieh C-C, Ko W-C, Lee C-C. Antimicrobial escalation is not
beneficial for Gram-negative bacteremia in adults who remained critically ill after appropriate
empirical therapy. Journal of infection and chemotherapy: official journal of the Japan Society
of Chemotherapy. 2020 Sep;26(9):933-940.
38. Roger P-M, et al. Risk Factors for Unnecessary Antibiotic Therapy: A Major Role for Clinical
Management. Clin Infect Dis. 2019 Jul;69(3):466-472.
39. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr.
2021 Oct;44(5):161-164.
40. Bassetti M, Vena A, Giacobbe DR, et al. Risk Factors for Intra-Abdominal Candidiasis in
Intensive Care Units: Results from EUCANDICU Study. Infect Dis Ther. 2022 Apr;11(2):827840.
41. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia
due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011
Aug;39(4):319-325.
42. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial
therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011
4th European Conference on Infections in Leukemia. Haematologica. 2013 Dec;98(12):18261835.
43. Ly WJ, Brown EE, Pedretti Z, Auten J, Wilson WS. Evaluation of early de-escalation of
empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large
academic medical center.J Oncol Pharm Pract. 2023 Mar;29(2):305-310.
44. Petteys MM, Kachur E, Pillinger KE, He J, Copelan EA, Shahid Z. Antimicrobial deescalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of
unknown origin. J Oncol Pharm Pract. Apr 2020;26(3):632-640.
45. Ohji G, Doi A, Yamamoto S, Iwata K. Is de-escalation of antimicrobials effective? A
systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:71-79.
129